AstraZeneca, Daiichi Sankyo’s Enhertu approved for breast cancer in China

The National Medical Products Administration (NMPA) of China has granted approval to AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for use as a monotherapy in ... Read More